• Profile

Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis

Annals of Rheumatic Diseases Feb 12, 2022

Researchers examined how disease modifying antirheumatic drugs (DMARD) combination and monotherapy are associated with an immune response to an inactivated SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA).

  • Seroconversion (SC) of anti-SARS-CoV-2 immunoglobulin G (IgG) and neutralizing antibodies (NAb) induced by the inactivated vaccine (CoronaVac) were analyzed in this phase 4 prospective study of patients with RA in comparison to controls (CG).

  • Moderate but lower SC (61.8% vs 94.2%) and NAb positivity (45% vs 78.6%) were recorded in patients with RA in comparison to CG after full vaccination.

  • Immunogenicity was adversely affected by nearly all DMARD combinations, whereas this response was also hampered by a more restricted number of drugs (methotrexate/tofacitinib/abatacept/tocilizumab) as monotherapy.

  • Considering these findings, researchers emphasize the necessity for a broader approach, not limited to specific drugs, to improve vaccine response for this population.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen